Report: FDA Set to Unban RFK Jr.’s Favorite Peptides

FDA is reportedly preparing to lift a compounding ban on over a dozen peptides (RFK Jr. said ~14; 19 peptides were added to Category 2 in Sept 2023), reversing last year's restrictions. The move would expand legal compounding of popular peptides (e.g., BPC-157, LL-37, epitalon) and likely benefit compounding pharmacies, peptide suppliers and niche biotech players, but the magnitude of revenue upside is unclear. Significant safety concerns persist (FDA has cited deaths possibly linked to GHRP-2 and limited human data), and the policy reversal remains politically contingent, so regulatory and clinical risk will constrain investment conviction.

Analysis

The immediate winners are narrow: licensed compounding specialists and the CDMO/CRO ecosystem that supplies peptide synthesis, formulation, and analytical testing. Expect a near-term (weeks–3 months) volume bump as prescriptions move from gray-market channels into regulated compounding pharmacies, but capacity constraints in peptide-grade synthesis and analytical labs mean pricing and lead-times — not just unit volumes — will re-rate margins for capable providers.

Second-order effects matter: tighter supply for peptide-grade building blocks could push up input costs across small-molecule and biologic CDMOs, favoring vertically integrated or diversified manufacturers that can reallocate capacity. Conversely, payor behavior (non-coverage), state-level enforcement, or the first high-profile adverse event could compress demand quickly, making the upside highly binary and front-loaded.

Timing and catalysts: watch FDA communications, MedWatch adverse event disclosures, state AG enforcement actions, and quarterlies from CDMOs/CROs for utilization/mix commentary over the next 6–12 months. The path to durable commercial peptide markets is multi-year — durable winners will be firms that capture scale in manufacturing/testing or distribution while surviving episodic regulatory scrutiny, not the early hype-driven DTC suppliers.

Key Decisions for Investors

• Long IMPR (Imprimis) via 3–9 month call exposure or a call spread (size 1–2% NAV): asymmetric, binary upside if compounding volumes re-start quickly. Target: 100%+ return if revenue pick-up persists for two consecutive quarters; risk control: limit premium allocation and take profits on 50% move, loss cut at 50% of premium.
• Buy CTLT (Catalent) stock or 9–18 month calls (size 2% NAV): CDMOs should capture higher-margin peptide work and pricing power from constrained peptide synthesis capacity. Target: 25–40% upside if peptide-related utilization rises 3–6 percentage points within 12 months; hard stop: 20% share-price drawdown or negative utilization commentary.
• Long IQV (IQVIA) or CRL (Charles River) 6–12 month exposure (size 1–2% NAV) to capture increased analytical and early-stage trial demand. Target: 15–25% upside if peptide testing/early-stage programs grow; downside limited by diversified revenue bases—reduce position on 1) visible decline in peptide test volumes or 2) regulatory crackdowns limiting clinical activity.